Lesson plan

CU-13001

CU-13001 is a 15-lipoxygenase (15-LOX, ALOX15) inhibitor which is under development for the treatment of Parkinson's disease. It is taken orally. It is thought that 4-hydroxynonenal (4-HNE), a product of 15-LOX, may be involved in the etiology of Parkinson's disease, and that by inhibiting 4-HNE formation, CU-13001 theoretically may be able to prevent or slow the progression of Parkinson's disease. The drug is under development by Acurex Biosciences. As of September 2024, it is in the preclinical research stage of development for Parkinson's disease. The chemical structure of CU-13001 does not yet appear to have been disclosed.

Back to article

Article summary

CU-13001 is a 15-lipoxygenase (15-LOX, ALOX15) inhibitor which is under development for the treatment of Parkinson's disease. It is taken orally. It is thought that 4-hydroxynonenal (4-HNE), a product of 15-LOX, may be involved in the etiology of Parkinson's disease, and that by inhibiting 4-HNE formation, CU-13001 theoretically may be able to prevent or slow the progression of Parkinson's disease. The drug is under development by Acurex Biosciences. As of September 2024, it is in the preclinical research stage of development for Parkinson's disease. The chemical structure of CU-13001 does not yet appear to have been disclosed.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.